Phase 2 Schizophrenia Trial, Recruiting NCT04959201 Sponsor: China Medical University Hospital Condition: Schizophrenia
Back to Schizophrenia

Phase 2 Schizophrenia Trial, Recruiting

NCT04959201
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been formally diagnosed with schizophrenia according to standard diagnostic guidelines (DSM-5).
  • People who still have symptoms of schizophrenia but whose condition has been stable (no major changes) for at least 3 months, and whose antipsychotic medication dose has stayed the same and will continue unchanged for the 12-week duration of the trial.
  • People whose symptom severity meets a minimum threshold score of 60 on a standard psychiatric rating scale called the PANSS (confirm with trial site).
  • People who are willing to take part and have signed a consent form agreeing to participate.

Who may not be able to join:

  • People who have a formal diagnosis of intellectual disability or a substance use disorder, including alcohol use disorder.
  • People who have a history of epilepsy, significant head injury, stroke, or other serious medical or brain/nervous system conditions (apart from schizophrenia) that could affect the trial results.
  • People whose routine blood or laboratory test results show clinically significant abnormalities (confirm with trial site for specific thresholds).
  • People who are pregnant or currently breastfeeding.
  • People who would be unable to follow the trial's procedures and requirements.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 886 4 22052121

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
China Medical University Hospital
Registry
ClinicalTrials.gov
Start date
30 November 2020
Est. completion
1 December 2026

Where this trial is recruiting

🇹🇼 Taiwan

Primary endpoints

Change of Positive and Negative Syndrome Scale (PANSS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov